Inventor · disambiguated record
Michael Pourdehnad
Also filed as: POURDEHNAD MICHAEL
18 granted patents·20 pending applications·68 citations·filing 2015–2025
92Inventor score
Top patents by PatentIndex Score
38 records- 0197US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 0294US9808451B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2016·Granted Nov 7, 2017·12 cites·19 claims
- 0392US9968596B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·8 cites·26 claims
- 0490US11666579B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jun 6, 2023·2 cites·21 claims
- 0590US11241423B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 8, 2022·2 cites·6 claims
- 0688US10245258B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2017·Granted Apr 2, 2019·8 cites·43 claims
- 0783US11390617B2Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jul 19, 2022·1 cites·31 claims
- 0883US10689708B2Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugsCELGENE CORP·Filed 2016·Granted Jun 23, 2020·3 cites·11 claims
- 0982US11628172B2Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Apr 18, 2023·1 cites·25 claims
- 1080US2024400548A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2024·Application pending·0 cites
- 1179US2022387413A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 1278US12396995B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Aug 26, 2025·0 cites·34 claims
- 1378US2025352551A1Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2025·Application pending·0 cites
- 1477US12103923B2Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Granted Oct 1, 2024·0 cites·23 claims
- 1576US12178822B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dionCELGENE CORP·Filed 2023·Granted Dec 31, 2024·0 cites·26 claims
- 1676US2023158009A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2023·Application pending·0 cites
- 1775US10973822B2Combination therapy for treatment of hematological cancers and solid tumorsCELGENE CORP·Filed 2016·Granted Apr 13, 2021·3 cites·69 claims
- 1875US2025017941A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2024·Application pending·0 cites
- 1968US11590117B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Feb 28, 2023·0 cites·21 claims
- 2068US11583536B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted Feb 21, 2023·0 cites·41 claims
- 2168US2023210859A1Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2023·Application pending·0 cites
- 2265US2022362255A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Application pending·0 cites
- 2364US2018221361A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Application pending·0 cites
- 2463US12263190B2Methods and combinations for treatment and T cell modulationJUNO THERAPEUTICS INC·Filed 2019·Granted Apr 1, 2025·0 cites·33 claims
- 2560US2024207281A1Methods of treating b-cell lymphoma using combination therapyCELGENE CORP·Filed 2022·Application pending·0 cites
- 2659US2019175573A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2019·Application pending·0 cites
- 2758US2022387405A1Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamideCELGENE CORP·Filed 2022·Application pending·0 cites
- 2854US2025186503A1Methods and combinations for treatment and t cell modulationJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2953US12090147B2Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Sep 17, 2024·0 cites·18 claims
- 3052US2024197871A1Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphomaJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3152US2022378773A1Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapiesCELGENE CORP·Filed 2020·Application pending·0 cites
- 3252US2021102257A1Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor to responsiveness to drugsCELGENE CORP·Filed 2020·Application pending·0 cites
- 3349US2023149379A1Combination therapy for acute myeloid leukemiaCELGENE CORP·Filed 2021·Application pending·0 cites
- 3448US2019030018A1Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2018·Application pending·0 cites
- 3545US10159675B2Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2016·Granted Dec 25, 2018·0 cites·22 claims
- 3644US2022401483A1Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dioneJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3736US2017038387A1Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
- 3831US2017128448A1Combination therapy for cancerCELGENE CORP·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →